drugset / Trial / NCT03458923

Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.

NCT03458923

Phase 4 Unknown 30 enrolled Cairo University
RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to compare the effect of intravitreal non steroidal anti inflammatory (Diclofenac) versus the standard treatment of diabetic macular edema, intravitreal anti vascular endothelial growth factor (Ranibizumab), measuring central macular thickness changes and best corrected visual acuity.

Timeline

Start
2015-01
Primary completion
2018-06
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diclofenac Other / unclassified 500 ug Intravitreal
Comparator Ranibizumab Monoclonal antibody 0.5 mg Intravitreal